Sustained weight loss after treatment with a glucagon-like peptide-1 receptor agonist in an obese patient with schizophrenia and type 2 diabetes

Am J Psychiatry. 2013 Jun;170(6):681-2. doi: 10.1176/appi.ajp.2013.12101344.
No abstract available

Publication types

  • Case Reports
  • Letter
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Antipsychotic Agents / adverse effects
  • Antipsychotic Agents / therapeutic use
  • Clozapine / adverse effects
  • Clozapine / therapeutic use
  • Diabetes Mellitus, Type 2 / complications*
  • Female
  • Glucagon-Like Peptide 1 / analogs & derivatives*
  • Glucagon-Like Peptide 1 / therapeutic use
  • Glucagon-Like Peptide-1 Receptor
  • Glycated Hemoglobin / analysis
  • Humans
  • Liraglutide
  • Middle Aged
  • Obesity / chemically induced*
  • Obesity / complications
  • Receptors, Glucagon / agonists*
  • Schizophrenia / complications*
  • Schizophrenia / drug therapy
  • Weight Loss / drug effects*

Substances

  • Antipsychotic Agents
  • GLP1R protein, human
  • Glucagon-Like Peptide-1 Receptor
  • Glycated Hemoglobin A
  • Receptors, Glucagon
  • hemoglobin A1c protein, human
  • Liraglutide
  • Glucagon-Like Peptide 1
  • Clozapine